Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab

Daewoong Pharmaceutical

Status: Active, not recruiting

Conditions: Hypertension; Hyperlipidemias

Treatments: Drug: Rosuvastatin, Olmesartan Medoxomil

Study type: Observational

Funder types: Industry

Identifiers

NCT05411887

DWOS_OLO_004

Details and patient eligibility

About

The purpose of this study is to evaluate the effectiveness of Olostar Tablet on blood pressure and lipid profiles, obtain safety-related information for subgroups that failed to participate in the clinical trials, and to evaluate variables that affect treatment effectiveness.

Enrollment: 2,845 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. men and women over the age of 19
2. Patients who signed a written consent form to participate in the study
3. Patients who are eligible for Olostar tablet prescription according to domestic permission

Exclusion criteria

1. A person who falls under "2. Do not administer to the following patients" among the precautions for use in the user manual
2. Patients in hospital (hospitals only; nursing care facilities can be recruited)
3. A person who has been administered the study target drug or is being administered at the time of recruitment within 6 months based on the date of the study contract

Trial design

2,845 participants in 1 patient group

Experimental/ Olostar Tablet

Description:

Eligible Subjects who received Olostar Tablet treatment for 24 weeks. Dosage: 10/5mg, 10/10mg, 20/5mg, 20/10mg, 20/20mg, 40/10mg, 40/20mg

Treatment:

Drug: Rosuvastatin, Olmesartan Medoxomil